Haleon 6-K: Q3 2025 trading statement; 9:00am GMT Q&A call
Haleon plc filed a Form 6-K announcing its Q3 2025 trading statement is available online, including on its investor site and via the UK FCA’s National Storage Mechanism.
Rhea-AI Filing Summary
Haleon plc filed a Form 6-K announcing its Q3 2025 trading statement is available online, including on its investor site and via the UK FCA’s National Storage Mechanism.
The Company will host a short presentation and Q&A at 9:00am GMT (10:00am CET) on 30 October 2025, led by Chief Financial Officer Dawn Allen, with access via www.haleon.com/investors.
Dial-in details include UK: +44 (0) 808 189 0158; US: +1 855 979 6654; All other: +44 (0) 203 936 2999; passcode 407228. An archived webcast will be available later the same day.
Positive
- None.
Negative
- None.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Where can I access Haleon (HLN) Q3 2025 trading statement?
The statement is available at www.haleon.com/investors and via the FCA’s National Storage Mechanism; a specific RNS PDF link is provided.
When is Haleon’s Q3 2025 investor presentation and Q&A?
The session is scheduled for 9:00am GMT (10:00am CET) on 30 October 2025.
Who will host Haleon’s Q3 2025 presentation?
The presentation and Q&A will be hosted by Chief Financial Officer Dawn Allen.
How do I dial in to Haleon’s Q3 2025 Q&A call?
UK: +44 (0) 808 189 0158; US: +1 855 979 6654; All other: +44 (0) 203 936 2999; passcode 407228.
Will a replay of Haleon’s Q3 2025 call be available?
Yes. An archived webcast of the Q&A will be available later the same day at www.haleon.com/investors.
What are Haleon’s tickers and business focus?
Haleon trades as LSE/NYSE: HLN and is a global consumer health company with brands such as Sensodyne, Panadol, and Voltaren.
How can I contact Haleon’s investor relations team?
Email investor-relations@haleon.com; investor contacts include Jo Russell and Rakesh Patel.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2025
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit Number
|
Description
|
|
99.1
|
30
October 2025 - “Haleon 2025 Q3 Trading
Statement”
|
|
99.2
|
30
October 2025 - “Haleon
2025 Q3 Trading Statement”
|
99.1
Haleon plc: 2025 Q3 Trading Statement
30 October 2025: Haleon plc (the "Company" or “Haleon”) today
announces its Q3 trading statement for the year ending 31 December
2025 is available at: http://www.rns-pdf.londonstockexchange.com/rns/4049F_1-2025-10-29.pdf.
The Q3 trading statement will also be available on the Haleon
website www.haleon.com/investors,
and has been submitted in full unedited text to the Financial
Conduct Authority's National Storage Mechanism and will shortly be
available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Presentation for analysts and shareholders
A short presentation followed by Q&A will be hosted by Dawn
Allen, Chief Financial Officer at 9:00am GMT (10:00am CET) on 30
October 2025, which can be accessed at www.haleon.com/investors.
For analysts and shareholders wishing to ask questions on the
Q&A call, please use the dial-in details below which will have
a Q&A facility:
|
UK:
|
+44 (0) 808 189 0158
|
|
US:
|
+1 855 979 6654
|
|
All other:
|
+44 (0) 203 936 2999
|
|
Passcode:
|
407228
|
An archived webcast of the Q&A call will be available later on
the day of the results and can be accessed at www.haleon.com/investors.
Amanda Mellor
Company Secretary
Enquiries
|
Investors
|
Media
|
||
|
Jo
Russell
|
+44
7787 392441
|
Zoë
Bird
|
+44
7736 746167
|
|
Rakesh
Patel
|
+44
7552 484646
|
Victoria
Durman
|
+44
7894 505730
|
|
Email: investor-relations@haleon.com
|
Email: corporate.media@haleon.com
|
||
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with
a purpose to deliver better everyday health with humanity. Haleon's
product portfolio spans six major categories - Oral Health,
Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory
Health, Digestive Health and Therapeutic Skin Health and Other. Its
long-standing brands - such as Advil, Centrum, Otrivin,
Panadol, parodontax, Polident, Sensodyne, Theraflu and
Voltaren - are built on trusted
science, innovation and deep human
understanding.
For more information please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
|
Date:
October 30, 2025
|
By:
|
/s/
Amanda Mellor
|
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|